Also trades as: 0LB2.L (LSE) · $vol 0M
SUPN NASDAQ
Supernus Pharmaceuticals, Inc.
1W: +2.3%
1M: -4.4%
3M: -14.6%
YTD: -17.6%
1Y: -21.6%
3Y: +71.5%
5Y: +32.9%
$40.96
+0.19 (+0.47%)
After Hours: $44.62 (+3.66, +8.95%)
Weekly Expected Move ±6.0%
$36
$38
$41
$43
$46
Credit Risk of going bust: lower than 91% of companies Debt: 1.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.9%), Supernus Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $40.2M against a stock market value of $2.37B.
Distance to default 14.33 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $10.7M (short-term plus half of long-term), stock volatility 37.7%; Altman Z 4.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99.9%), Supernus Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $40.2M against a stock market value of $2.37B.
Distance to default 14.33 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $10.7M (short-term plus half of long-term), stock volatility 37.7%; Altman Z 4.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
-0.22
Neutral
1 bullish
1 neutral
2 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (87)
Oppenheimer's top 50 small- and mid-cap Sell ideas
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
MSG Rangers and Huron Consulting Group to join S&P SmallCap 600
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
Bank of America Corp DE Buys New Stake in Supernus Pharmaceuticals, Inc. $SUPN
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Allworth Financial LP Invests $2.36 Million in Supernus Pharmaceuticals, Inc. $SUPN
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.
Key deals this week: Bending Spoons, Advanced Micro Devices, Visa, Prologis, and more
California State Teachers Retirement System Grows Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN
Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
New Strong Buy Stocks for August 7th
Best Value Stocks to Buy for August 7th
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Why Supernus Pharmaceuticals Stock Topped the Market Today
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates
Supernus Announces Second Quarter 2026 Financial Results
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Dimensional Fund Advisors LP
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Supernus Pharmaceuticals to Participate in June Investor Conferences
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Supernus (SUPN) Q1 2026 Earnings Transcript
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript
Supernus Announces First Quarter 2026 Financial Results
Earnings Scheduled For May 5, 2026
Supernus Pharmaceuticals Q1 2026 Earnings Preview
Bausch Health (BHC) Lags Q1 Earnings Estimates
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Choreo LLC Buys New Shares in Supernus Pharmaceuticals, Inc. $SUPN
Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals, Inc. $SUPN
Aberdeen Group plc Acquires New Shares in Supernus Pharmaceuticals, Inc. $SUPN
Supernus finalizes $350M asset acquisition of Navitor’s SPN-820
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.
Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc.
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN
Citigroup Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN
Supernus outlines $840M–$870M 2026 revenue target as ONAPGO supply normalizes and growth brands accelerate
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus Pharmaceuticals GAAP EPS of $0.07 beats by $0.28, revenue of $211.6M beats by $16.44M
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings after the close Tuesday
Supernus Pharmaceuticals Q4 2025 Earnings Preview
Supernus Pharmaceuticals to Participate in March Investor Conferences
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Lunai Bioworks, Inc. Issues Letter to Shareholders
15,525 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by AdvisorShares Investments LLC
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
SG Americas Securities LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $61.60 Average Price Target from Analysts
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $31,552.40 in Stock
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $63.25 Consensus PT from Brokerages
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 1,161 Shares of Supernus Pharmaceuticals, Inc. $SUPN
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Bank of New York Mellon Corp Purchases 11,877 Shares of Supernus Pharmaceuticals, Inc. $SUPN